Results 31 to 40 of about 310,837 (298)

Epigenetic regulation as a promising tool for treatment of atherosclerosis

Frontiers in Bioscience-Scholar, 2020
Atherosclerosis is one of the leading causes of death from cardiovascular disease (CVD) that primarily involves mid size and large arteries. Atherosclerosis is associated with disruption of lipid metabolism and chronic inflammatory processes.
Daria Skuratovskaia, Maria Vulf, Aleksandra Komar, Elena Kirienkova, Larisa Litvinova   +4 more
doaj   +1 more source

TRAF2 binds to TIFA via a novel motif and contributes to its autophagic degradation

FEBS Letters, EarlyView.
TRAF family members couple receptor signalling complexes to downstream outputs, but how they interact with these complexes is not always clear. Here, we show that during ADP‐heptose signalling, TRAF2 binding to TIFA requires two short sequence motifs in the C‐terminal tail of TIFA, which are distinct from the TRAF6 binding motif.
Tom Snelling, Kodi Hunter, Celest W. S. Tay, Nicola T. Wood, Philip Cohen   +4 more
wiley   +1 more source

Advances of non-viral nanometer vectors delivery systemfor siRNA

生物医学转化, 2021
The delivery of small interfering RNA is now mainly through viral vector delivery, chemicalmodification delivery, microinjection delivery, and non-viral nanometer vector delivery.
Geng Xiang, Huang Meizhou, Li Jianyong
doaj   +1 more source

Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM

Molecular Oncology, EarlyView.
CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.
Julia Latowska‐Łysiak, Żaneta Zarębska, Marcin P. Sajek, Adriana Grabowska, Alessia Buratin, Paweł Głodowicz, Julia O. Misiorek, Konrad Kuczyński, Stefania Bortoluzzi, Marek Żywicki, Jan G. Kosiński, Agnieszka Rybak‐Wolf, Rafał Piestrzeniewicz, Anna M. Barciszewska, Katarzyna Rolle   +14 more
wiley   +1 more source

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

Molecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini, Giada Mele, Marika Attili, Maria Rita Assenza, Fulvio Saccoccia, Francesca Sardina, Cinzia Rinaldo, Roberto Massari, Nicola Tirelli, Alfredo Pontecorvi, Fabiola Moretti   +10 more
wiley   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]

Journal of Lipid Research, 2011
Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks ...
Brandon Ason, Samnang Tep, Jr. Harry R. Davis, Yiming Xu, Glen Tetzloff, Beverly Galinski, Ferdie Soriano, Natalya Dubinina, Lei Zhu, Alice Stefanni, Kenny K. Wong, Marija Tadin-Strapps, Steven R. Bartz, Brian Hubbard, Mollie Ranalletta, Alan B. Sachs, W. Michael Flanagan, Alison Strack, Nelly A. Kuklin   +18 more
doaj  

Synthesis of Cationic and Ionizable Amphiphiles Based on Heminal Aminodiol as Potential siRNA Delivery Systems

Тонкие химические технологии, 2019
Research methods based on the use of RNA interference mechanisms are now included among the basic methods of molecular biology. Drugs based on siRNA are being developed for the treatment of cancer, infectious diseases and other pathologies that are ...
Z. G. Denieva, U. A. Budanova, Yu. L. Sebyakin   +2 more
doaj   +1 more source

A more accurate analysis of maternal effect genes by siRNA electroporation into mouse oocytes

The Journal of Reproduction and Development, 2023
Maternal RNA and proteins accumulate in mouse oocytes and regulate initial developmental stages. Sperm DNA combines with protamine, which is exchanged after fertilization with maternal histones, including H3.3; however, the effect of H3.3 on development ...
Takuto YAMAMOTO, Shinnosuke HONDA, Issei IDEGUCHI, Motoki SUEMATSU, Shuntaro IKEDA, Naojiro MINAMI   +5 more
doaj   +1 more source

Where should siRNAs go: applicable organs for siRNA drugs

Experimental & Molecular Medicine, 2023
AbstractRNA interference mediated by small interfering RNAs (siRNAs) has been exploited for the development of therapeutics. siRNAs can be a powerful therapeutic tool because the working mechanisms of siRNAs are straightforward. siRNAs determine targets based on their sequence and specifically regulate the gene expression of the target gene.
Insook Ahn, Chanhee S. Kang, Jinju Han
openaire   +3 more sources